CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens
出版年份 2017 全文链接
标题
CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-10-05
DOI
10.1038/s41598-017-12513-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis
- (2017) Kelby W. Wegner et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The Cellular Thermal Shift Assay: A Novel Biophysical Assay for In Situ Drug Target Engagement and Mechanistic Biomarker Studies
- (2016) Daniel Martinez Molina et al. Annual Review of Pharmacology and Toxicology
- RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury
- (2016) K Newton et al. CELL DEATH AND DIFFERENTIATION
- Generation of small molecules to interfere with regulated necrosis
- (2016) Alexei Degterev et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors
- (2016) Philip A. Harris et al. JOURNAL OF MEDICINAL CHEMISTRY
- RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS
- (2016) Yasushi Ito et al. SCIENCE
- CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil
- (2016) Helena Almqvist et al. Nature Communications
- Target Engagement in Lead Generation
- (2015) Timothy B. Durham et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis
- (2015) D A Rodriguez et al. CELL DEATH AND DIFFERENTIATION
- Necrostatin-1 alleviates reperfusion injury following acute myocardial infarction in pigs
- (2015) Stefan Koudstaal et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- An analysis of the attrition of drug candidates from four major pharmaceutical companies
- (2015) Michael J. Waring et al. NATURE REVIEWS DRUG DISCOVERY
- Structure Guided Design of Potent and Selective Ponatinib-Based Hybrid Inhibitors for RIPK1
- (2015) Malek Najjar et al. Cell Reports
- Activation of Necroptosis in Multiple Sclerosis
- (2015) Dimitry Ofengeim et al. Cell Reports
- Cutting Edge: RIPK1 Kinase Inactive Mice Are Viable and Protected from TNF-Induced Necroptosis In Vivo
- (2014) Apostolos Polykratis et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: RIP1 Kinase Activity Is Dispensable for Normal Development but Is a Key Regulator of Inflammation in SHARPIN-Deficient Mice
- (2014) S. B. Berger et al. JOURNAL OF IMMUNOLOGY
- NQO2 Is a Reactive Oxygen Species Generating Off-Target for Acetaminophen
- (2014) Teemu P. Miettinen et al. MOLECULAR PHARMACEUTICS
- The cellular thermal shift assay for evaluating drug target interactions in cells
- (2014) Rozbeh Jafari et al. Nature Protocols
- The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism
- (2013) James M. Murphy et al. IMMUNITY
- Target validation using chemical probes
- (2013) Mark E Bunnage et al. Nature Chemical Biology
- Translational PET imaging research
- (2013) Richard J. Hargreaves et al. NEUROBIOLOGY OF DISEASE
- Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
- (2013) D. M. Molina et al. SCIENCE
- Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis
- (2013) Philip A. Harris et al. ACS Medicinal Chemistry Letters
- Positron emission tomography molecular imaging for drug development
- (2011) Paul M. Matthews et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
- (2011) Cris S Constantinescu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
- (2011) Paul Morgan et al. DRUG DISCOVERY TODAY
- RIP Kinase-Dependent Necrosis Drives Lethal Systemic Inflammatory Response Syndrome
- (2011) Linde Duprez et al. IMMUNITY
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- Physiological levels of ATP negatively regulate proteasome function
- (2010) Hongbiao Huang et al. CELL RESEARCH
- Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α
- (2009) Sudan He et al. CELL
- Identification of RIP1 kinase as a specific cellular target of necrostatins
- (2008) Alexei Degterev et al. Nature Chemical Biology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More